Affluent Medical to Acquire Caranx Medical and Artedrone, Forming AI-Driven Cardiovascular Company Carvolix
Paris-based Affluent Medical has entered into binding agreements to acquire Caranx Medical and Artedrone, a move that will combine three French MedTech companies into a new entity named Carvolix. The acquisitions, expected to close by the end of January 2026, will be completed through a cashless transaction valued at €16.6 million for Caranx Medical and €11.4 million for Artedrone, paid entirely in newly issued Affluent shares, with additional earn-out provisions tied to regulatory and commercial milestones.
The transaction is intended to integrate autonomous mini-robotics, artificial intelligence, and implantable device technologies to support interventional cardiology and stroke care. Carvolix will focus on transcatheter cardiac valve replacement and mechanical thrombectomy, two areas where procedure adoption remains limited despite large patient populations. The combined addressable market for these indications is estimated at €23 billion by 2030, according to the companies.
A key near-term asset within the combined portfolio is TAVIPILOT Software, an AI-based guidance system for transcatheter aortic valve implantation. The software received FDA clearance in July 2025, with U.S. commercialization expected to begin in the first quarter of 2026. Additional programs include robotic systems for stroke intervention and implantable valve technologies, which are at earlier clinical and development stages.
Sebastien Ladet, designated chief executive officer of Carvolix, said the combination is intended to expand access to complex cardiovascular procedures by improving efficiency in catheterization laboratories. Philippe Pouletty, chief executive officer of Truffle Capital, which led the transaction, stated that the consolidation aims to reduce development risk and accelerate product delivery by aligning complementary technologies under a single platform.
In parallel with the acquisitions, Affluent Medical has launched a financing round of up to €30 million, led by Truffle Capital and Edwards Lifesciences. A first tranche of €10 million has been secured at a share price of €2.34, representing a premium to the company’s recent trading levels. The proceeds are expected to extend Affluent’s cash runway into mid-2026 and support ongoing clinical, regulatory, and early commercialization activities across the combined product portfolio.
